That is, olanzapine upregulates PCSK9 via LXRα signaling, thereby promoting the expression of target hepatic lipogenesis-associated genes, which contributes to lipid accumulation in the liver and, consequently, the development of NAFLD. The gene discussed is PCSK9; the disease is metabolic dysfunction-associated steatotic liver disease.